 "Lupin launches drug to control postpartum hemorrhage after USFDA nod")
Drug maker Lupin on Monday launched Methylergonovine Maleate tablets, used for prevention and control of postpartum hemorrhage, in the American market.
The company has launched the product in the US after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
Lupin's product is the generic equivalent of Novartis Pharmaceuticals Corp's Methergine which is indicated for prevention and control of postpartum hemorrhage.
As per the latest industry estimates, Methylergonovine Maleate tablets had annual sales of around $71.5 million in the US.
Lupin shares were trading 1.18 per cent up at Rs 772.10 on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app